Результаты поиска

Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.

Cancer-associated thrombosis is one of the most common and serious complications in oncology patients, contributing significantly to morbidity and mortality. This prothrombotic state is driven by cancer-related factors, systemic inflammation, and treatment-induced endothelial injury. Anticoagulation management in these patients is challenging, as both thrombotic and bleeding risks must be carefully balanced, particularly in those with cardiovascular comorbidities. This review examines the complexities of anticoagulation in cancer-associated thrombosis through three clinical cases. Case 1 focus

Совпадение в полном тексте источника
… When considering the use of more potent P2Y12 inhibitors, such as ticagrelor or prasugrel, it’s important to carefully evaluate both bleeding and thrombotic risks, as these agents may increase bleeding potential in high-risk patients [ 56 ]. …

Purinergic Signalling: Therapeutic Developments.

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990's when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and the

Совпадение в полном тексте источника
… The efficacy of the P2Y 12 antagonists ticagrelor and prasugrel are not affected in AF ( Ondrakova et al., 2016 ). The roles of adenosine and ATP in atrial arrhythmias and fibrillation have been discussed ( Jared Bunch, 2015 ; Belhassen and Michowitz, 2016 ). … Other P2Y 12 antagonists have been developed, including ticlopidine, cangrelor, ticagrelor, prasugrel, elinogrel, BX 667, and PSB 0739. P2Y 1 R antagonists also have antithrombotic actions and have been recommended as a complement to current P2Y 12 anti-platelet strategies. …

Left Atrial Appendage Occlusion in Cancer-Associated Atrial Fibrillation: Who, When, and How to Manage Antithrombotic Therapy.

BackgroundCancer-associated atrial fibrillation (AF) is increasingly common, posing dual risks of thrombosis and bleeding. Long-term oral anticoagulation is often limited in these patients due to drug interactions, thrombocytopenia, and treatment-related bleeding. Left atrial appendage occlusion (LAAO) offers a non-pharmacological alternative for stroke prevention, yet its optimal use in cancer remains uncertain.MethodsWe conducted a narrative review of studies from 2009 to October 2025 across PubMed, Embase, and Google Scholar, including randomized trials, observational studies, registries, c

Совпадение в полном тексте источника
… Stronger P2Y12 inhibitors like ticagrelor or prasugrel are generally avoided in oncology patients because of excess bleeding risk. 46 , 54 Tailored Strategies in Cancer Patients Patients with AF pose a special problem for cancer patients due to the coexistence of hypercoagulability and high bleeding …

Cardiogenic shock among cancer patients.

Sophisticated cancer treatments, cardiovascular risk factors, and aging trigger acute cardiovascular diseases in an increasing number of cancer patients. Among acute cardiovascular diseases, cancer treatment, as well as the cancer disease itself, may induce a cardiogenic shock. Although increasing, these cardiogenic shocks are still relatively limited, and their management is a matter of debate in cancer patients. Etiologies that cause cardiogenic shock are slightly different from those of non-cancer patients, and management has some specific features always requiring a multidisciplinary appro

Совпадение в полном тексте источника
… Aspirin and clopidogrel should be preferred to ticagrelor and prasugrel because of the high bleeding risk and limited data regarding both efficacy and safety in patients with active cancer ( 13 ). …

Targeting the NLRP3 inflammasome in kidney disease: molecular mechanisms, pathogenic roles, and emerging small-molecule therapeutics.

Inflammatory responses represent a core pathological process driving the progression of both acute and chronic kidney diseases. As a key effector of the innate immune system, the NLRP3 inflammasome is widely activated in renal resident cellsand infiltrating immune cells, positioning it as a critical nexus linking metabolic dysregulation, cellular stress, and tissue injury. Accumulating preclinical and clinical evidence in recent years demonstrates that aberrant activation of the NLRP3 inflammasome directly promotes glomerular damage, tubulointerstitial inflammation, fibrosis, and vascular dysf

Совпадение в полном тексте источника
… NPBB is a Cl − channel blocker that can maintain low levels of intracellular Cl − , thereby inhibiting the activation of NLRP3; the antiplatelet drug ticagrelor acts on Cl − channels by inducing the degradation of channel proteins and inhibiting the membrane localization of chloride channel proteins …

Antibodies to watch in 2021.

In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed an

Совпадение в полном тексте источника
… . | Bentracimab (PB2452) | Human Fab | Ticagrelor | Phase 3 | Reversal of the antiplatelet effects of ticagrelor ( NCT04286438 ) Pfizer | Marstacimab (PF-06741086) | Human IgG1 | Tissue factor pathway inhibitor | Phase 3 | Hemophilia A or B ( NCT03938792 ) Taisho Pharmaceutical Co., Ltd. | Ozoralizumab …

Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.

As a fundamental process of innate immunity, inflammation is associated with the pathologic process of various diseases and constitutes a prevalent risk factor for both cancer and cardiovascular disease (CVD). Studies have indicated that several non-steroidal anti-inflammatory drugs (NSAIDs), including Meloxicam, may prevent tumorigenesis, reduce the risk of carcinogenesis, improve the efficacy of anticancer therapies, and reduce the risk of CVD, in addition to controlling the body's inflammatory imbalances. Traditionally, most NSAIDs work by inhibiting cyclooxygenase (COX) activity, thereby b

Совпадение в полном тексте источника
… Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke. J. Neuroimmune Pharmacol. 2021;16:835–853. doi: 10.1007/s11481-020-09978-9. 167. …

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review.

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Arterial thromboembolism, including myocardial infarction and stroke, is also prevalent. Risk differs in subgroups, with higher rates observed in specific cancers including pancreas, stomach, and multiple myeloma. Thromboprophylaxis is recommended for most patients with active cancer hospitalized for medical illnesses and after major cancer surgery. Outpatient thromboprophylaxis is not routinely recommended, but emerging data suggest

Совпадение в полном тексте источника
… Because of a lack of evidence, prasugrel, ticagrelor, and glycoprotein IIb/IIIa inhibitors should not be used in patients with platelet counts of <50,000/ml. Revascularization is imperative in the setting of critical ischemia or infarction. …

Bone Research Society 2021 Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive ther

Совпадение в полном тексте источника
… APS patients with recurrent arterial or venous thrombosis on standard-intensity VKA, addition of LDA, increase of INR target to 3.0–4.0 or change to LMWH. 16 , 40 There is a lack of data about the use of other antiplatelet agents in patients with aPL/thrombotic APS, including clopidogrel, prasugrel, ticagrelor …

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Real-world evidence (RWE) is emerging as a fundamental component of the post-marketing evaluation of medicinal products. Even though the focus on RWE studies has increased in Colombia, the availability of secondary data sources to perform this type of research is not well documented. Thus, we aimed at identifying and characterizing secondary data sources available in Colombia. We performed a systematic literature review on PubMed, EMBASE, and VHL using a combination of controlled vocabulary and keywords for the concepts of electronic health records, epidemiologic studies and Colombia. A total

Совпадение в полном тексте источника
… Cost‐effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia. Biomedica. 2015;35:531‐540. 152. Mejía GA, Olarte‐Parra C, Pedraza A, Rivera JB, Benavides CA. …

Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.

Cardiovascular diseases and cancer are the two primary causes of mortality worldwide. Although traditionally regarded as distinct pathologies, they share numerous pathophysiological mechanisms and risk factors, including chronic inflammation, insulin resistance, obesity, and metabolic dysregulation. Notably, several cancers have been identified as closely linked to cardiovascular diseases, including lung, breast, prostate, and colorectal cancers, as well as hematological malignancies, such as leukemia and lymphoma. Additionally, renal and pancreatic cancers exhibit a significant association wi

Совпадение в полном тексте источника
… Novel antiplatelet agents, such as clopidogrel, prasugrel, ticagrelor, and vorapaxar, have been implicated in heightened neoplastic risk [ 122 ]. …

Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their association with thrombosis presents significant clinical challenges. Patients with cancer already exhibit elevated risks for venous thromboembolism and arterial thrombosis, with treatment modalities like chemotherapy further exacerbating this risk. Emerging evidence suggests that ICIs contribute to thrombotic events through multifactorial mechanisms, including immune dysregulation, T cell activation, endothelial dysfunction, elevated tissue factor expression, and impaired fibrinolysis. Additional risk factors

Совпадение в полном тексте источника
… Current antiplatelet agents, such as P2Y12 receptor antagonists (clopidogrel, prasugrel, and ticagrelor), thrombin-activated receptor-1 antagonists, and αIIbβ3 inhibitors (abciximab, eptifibatide, and tirofiban), exhibit strong antithrombotic effects but are limited in clinical use due to bleeding risks …

POSTER PRESENTATIONS

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме МКАРЕ 2023 77th Национальный конгресс &quot; СИААРТИ &quot;

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Артериальный тромбоэмболизм

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… AA‐inducible platelet aggregation by LTA and MEA did not correlate in prasugrel‐ and ticagrelor‐treated patients. … Conclusions : On‐treatment residual ADP‐inducible platelet reactivity by LTA and MEA shows a significant correlation in prasugrel‐ but not ticagrelor‐treated patients. …

Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.

Postoperative recurrence remains a major obstacle to durable remission in patients with solid tumors, even after complete macroscopic resection. Growing evidence suggests that surgery creates a transient yet highly permissive biological window characterized by inflammatory signaling, coagulation activation, endothelial disruption, and systemic immune suppression. Together, these processes foster a protective niche that enables microscopic residual disease to evade immune surveillance and initiate metastatic outgrowth. Although modern adjuvant therapies have improved outcomes, their effectivene

Neutrophil extracellular traps in homeostasis and disease.

Neutrophil extracellular traps (NETs), crucial in immune defense mechanisms, are renowned for their propensity to expel decondensed chromatin embedded with inflammatory proteins. Our comprehension of NETs in pathogen clearance, immune regulation and disease pathogenesis, has grown significantly in recent years. NETs are not only pivotal in the context of infections but also exhibit significant involvement in sterile inflammation. Evidence suggests that excessive accumulation of NETs can result in vessel occlusion, tissue damage, and prolonged inflammatory responses, thereby contributing to the

ISEV2019 Abstract Book

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Antiplatelet drug ticagrelor decreased concentrations of PEVs ( p = 0.03), compared to less potent clopidogrel but did not affect EEVs and RBC-EVs. In turn, concentrations of EEVs, but not PEVs and RBC-EVs, positively correlated with the dose of atorvastatin ( p < 0.001). … During treatment, ticagrelor decreased PEV concentrations, atorvastatin increased EEV concentrations and carvedilol increased RBC-EV concentrations, suggesting that EVs might be used to monitor AMI treatment. …

Abstracts from the World Congress of Cardiology/Brazilian Congress of Cardiology 2022

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.